Quick Answer
TENAX THERAPEUTICS, INC. reported Diluted EPS of $1.34 per share (loss) for fiscal year 2025.
TENAX THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.34 | -16.5% |
| 2024 | -$1.15 | +96.3% |
| 2023 | -$31.04 | -1045.4% |
| 2014 | -$2.71 | +59.4% |
| 2013 | -$6.68 | +52.5% |
| 2012 | -$14.07 | -3026.7% |
| 2011 | -$0.45 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | -110.5% | -48.1% |
| June 30, 2025 | -$0.27 | +85.2% | +3.6% |
| March 31, 2025 | -$0.28 | +91.0% | -47.4% |
| September 30, 2024 | -$0.19 | — | +89.6% |
| June 30, 2024 | -$1.83 | — | +41.3% |
| March 31, 2024 | -$3.12 | — | -3020.0% |
| January 31, 2015 | -$0.10 | +77.3% | +28.6% |
| October 31, 2014 | -$0.14 | +88.8% | -75.0% |
- TENAX THERAPEUTICS, INC. showed a decrease of -16.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, TENAX THERAPEUTICS, INC.’s diluted eps has declined by 197.8% (from $0.45 per share (loss) to $1.34 per share (loss)).
- The most recent figure is from TENAX THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: